CENTOGENE N.V. (CNTG): Price and Financial Metrics


CENTOGENE N.V. (CNTG): $0.79

0.03 (+4.59%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

CNTG Stock Summary

  • CNTG's price/sales ratio is 0.15; that's higher than the P/S ratio of merely 3.65% of US stocks.
  • As for revenue growth, note that CNTG's revenue has grown -37.79% over the past 12 months; that beats the revenue growth of just 5.14% of US companies in our set.
  • In terms of volatility of its share price, CNTG is more volatile than 93.82% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to CENTOGENE NV, a group of peers worth examining would be SOPH, AMSC, BASE, MASS, and RCEL.
  • Visit CNTG's SEC page to see the company's official filings. To visit the company's web site, go to www.centogene.com.

CNTG Price Target

For more insight on analysts targets of CNTG, see our CNTG price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $19.32 Average Broker Recommendation 1 (Strong Buy)

CNTG Stock Price Chart Interactive Chart >

Price chart for CNTG

CNTG Price/Volume Stats

Current price $0.79 52-week high $6.36
Prev. close $0.76 52-week low $0.68
Day low $0.76 Volume 55,100
Day high $0.80 Avg. volume 15,929
50-day MA $0.97 Dividend yield N/A
200-day MA $2.27 Market Cap 21.53M

CENTOGENE N.V. (CNTG) Company Bio


Centogene NV is a commercial-stage company. It focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. It operates through the following two segments: Pharmaceutical and Diagnostics. The Pharmaceutical segment provides services to pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery and patient monitoring. The Diagnostics segment provides targeted genetic sequencing and diagnostics services. The company was founded by Arndt Rolf and Christoph Ehlers in 2006 and is headquartered in Rostock, Denmark.


CNTG Latest News Stream


Event/Time News Detail
Loading, please wait...

CNTG Latest Social Stream


Loading social stream, please wait...

View Full CNTG Social Stream

Latest CNTG News From Around the Web

Below are the latest news stories about CENTOGENE NV that investors may wish to consider to help them evaluate CNTG as an investment opportunity.

Analyst: Centogene Leveraging The Largest BioDatabank For Rare Diseases

HC Wainwright initiated coverage on Germany-based Centogene NV (NASDAQ: CNTG) with a Buy rating and a price target of $2.50. Centogene is a diagnostics company. According to management, Centogene offers the broadest diagnostic testing portfolio for rare diseases, covering over 19,000 genes using over 10,000 different tests. The analyst notes that the company intends to strengthen its position in rare diseases by continuing to build its BioDatabank as the world's most comprehensive repository of

Yahoo | November 23, 2022

CENTOGENE Announces Changes to Supervisory Board, Including Appointment of Mary Sheahan

Adding significant financial expertise with an impressive track record in value creationCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the appointment of Mary Sheahan as a member of the Supervisory Board, to be confirmed at the Company’s next General Meeting of Shareholders. Ms. Sheahan will serve as a member ad int

Yahoo | November 21, 2022

CENTOGENE to Participate in Upcoming Conferences in November

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced its conference schedule for November 2022. The Company’s Pharma and CRO business development team and Diagnostics sales team will be attending events in the U.S. and Spain. CENTOGENE invites attendees to schedule one-on-one meetings. Please see additional details below:

Yahoo | November 10, 2022

CENTOGENE Launches Rare and Neurodegenerative Disease Biodata Network

Company’s launch of Biodata Network offers new portfolio of data-driven solutionsCollaboration with BC Platforms increases access to data-driven genomic insights via Global Data Partner Network, BCRQUEST.comTranche of 80,000 genetic sequences made accessible online for research and drug discovery CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerativ

Yahoo | November 3, 2022

CENTOGENE to Participate in Upcoming Partnering Conferences in October

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the commercial-stage essential biodata life science partner for rare and neurodegenerative diseases, today announced its partnering conference schedule for October 2022. Company management and the business development team will be attending events in the U.K. and Germany. CENTOGENE invites partners to schedule one-on-one meetings. Please see additional details below: European Socie

Yahoo | October 6, 2022

Read More 'CNTG' Stories Here

CNTG Price Returns

1-mo -12.11%
3-mo -39.23%
6-mo -68.84%
1-year -86.31%
3-year -93.80%
5-year N/A
YTD -84.89%
2021 -51.50%
2020 7.05%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7262 seconds.